Financial reports
10-K/A
2014 FY
Annual report (amended)
23 Feb 15
10-K
2014 FY
Annual report
18 Feb 15
10-Q
2014 Q3
Quarterly report
10 Nov 14
10-Q
2014 Q2
Quarterly report
6 Aug 14
10-Q
2014 Q1
Quarterly report
8 May 14
ARS
2013 FY
Annual report to shareholders
2 Apr 14
10-K
2013 FY
Annual report
18 Feb 14
10-Q
2013 Q3
Quarterly report
6 Nov 13
10-Q
2013 Q2
Quarterly report
8 Aug 13
10-Q
2013 Q1
Quarterly report
9 May 13
Current reports
8-K
Termination of a Material Definitive Agreement
23 Feb 15
8-K
Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech
12 Jan 15
8-K
NPS Pharma Reports Third-Quarter 2014 Financial Results
10 Nov 14
8-K
NPS Pharma Appoints Pierre Legault to Board of Directors
4 Nov 14
8-K
FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism
12 Sep 14
8-K
NPS Pharma Reports Second-Quarter 2014 Financial Results
6 Aug 14
8-K
Other Events
10 Jun 14
8-K
Regulation FD Disclosure
2 Jun 14
8-K
NPS Pharma Reports First-Quarter 2014 Financial Results
8 May 14
8-K
Departure of Directors or Certain Officers
7 May 14
Registration and prospectus
15-12G
Securities registration termination
5 Mar 15
25-NSE
Exchange delisting
23 Feb 15
POS AM
Prospectus update (post-effective amendment)
23 Feb 15
POS AM
Prospectus update (post-effective amendment)
23 Feb 15
POSASR
Automatic shelf registration (post-effective amendment)
23 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Feb 15
Proxies
DEF 14A
Definitive proxy
1 Apr 14
DEF 14A
Definitive proxy
29 Mar 13
DEF 14A
Definitive proxy
4 Apr 12
DEF 14A
Definitive proxy
15 Apr 11
PRE 14A
Preliminary proxy
5 Apr 11
DEFA14A
Additional proxy soliciting materials
8 Apr 10
DEF 14A
Definitive proxy
6 Apr 10
DEF 14A
Definitive proxy
13 Apr 09
DEFA14A
Additional proxy soliciting materials
15 May 08
DEF 14A
Definitive proxy
18 Apr 08
Other
EFFECT
Notice of effectiveness
24 Feb 15
EFFECT
Notice of effectiveness
24 Feb 15
CORRESP
Correspondence with SEC
20 Jan 15
UPLOAD
Letter from SEC
15 Jan 15
UPLOAD
Letter from SEC
15 Jan 15
UPLOAD
Letter from SEC
1 Dec 14
CT ORDER
Confidential treatment order
25 Nov 14
CORRESP
Correspondence with SEC
5 Nov 14
UPLOAD
Letter from SEC
23 Oct 14
CT ORDER
Confidential treatment order
21 Apr 14
Ownership
SC 13G/A
NPS Pharmaceuticals Inc
18 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
17 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
17 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
13 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
12 Feb 15
SC 13G
NPS Pharmaceuticals Inc
10 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
10 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
10 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
10 Feb 15
SC 13G/A
NPS Pharmaceuticals Inc
29 Jan 15